Human papillomavirus vaccine timing associated with eventual human papillomavirus diagnosis in women
Nearly all cases of cervical cancer are attributable to human papillomavirus (HPV), making it a significant women’s health issue. Though there have been advances in the prevention of HPV via vaccination, significant barriers continue to suppress vaccination rates for girls. Delaying vaccination until after sexual debut increases a woman’s chance of HPV infection, but there has been no quantification of this risk in the literature. The present study sought to address this gap via secondary data analysis with 173 female participants from the 2015–2016 National Health and Nutrition Examination Survey dataset. Results indicate that women in the sample who received the HPV vaccine after their sexual debut were 2.63 times more likely than women who receive the vaccine before their sexual debut to report an HPV diagnosis. These results have clear public and sexual health implications.
International Journal of STD and AIDS
Digital Object Identifier (DOI)
Zeglin, R. J., & Fetteroll, J. L. (2020). Human papillomavirus vaccine timing associated with eventual human papillomavirus diagnosis in women. International Journal of STD & AIDS, 31(10), 976–981. https://doi.org/10.1177/0956462420937168